UNSPSC 51313707: Bosentan monohydrate

This classification denotes an endothelin receptor antagonist with the molecular formula C27H29N5O6S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q326023R30, chemically known as 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2-bipyrimidin)-4-yl)benzenesulfornamide but more generally known as bosentan, which bears US NIH Compound Identifier 104865. Bosentan most often comes in basic and hydrate forms.

UNSPSC 51313707 Bosentan monohydrate is a Commodity code that, based on recent state and local opportunities, does not reflect actual procurement activity in the market. The three most recent opportunities tagged to this code—naloxone and drug deactivation systems procurement from Seminole County, Florida; a direct-to-manufacturer pharmacy initiative RFI from Texas Health and Human Services Commission; and a generic multi-source pharmaceuticals and OTC products cooperative purchasing RFP from Minnesota—involve controlled substances, pharmacy benefit management, and broad OTC categories respectively, none of which align with bosentan monohydrate, a pulmonary vasodilator used in endothelin receptor antagonist therapy. The code appears to be a misclassification or data entry error in the state and local procurement systems that tagged these opportunities.

No state or local government opportunities reflect genuine demand for bosentan monohydrate under this code. The presence of three pharmaceutical-adjacent solicitations does not signal active procurement in this specific commodity; rather, it suggests that state and local procurement systems may use broad pharmaceutical codes as default classifications when entering opportunities that do not fit narrower commodity categories. Business development professionals evaluating this code should treat it as inactive for bosentan monohydrate itself and instead track the broader pharmaceutical contracting activity visible in the Minnesota MMCAP generic pharmaceuticals RFP (due March 26, 2026, through the Minnesota Department of Administration) and Texas HHS direct-to-manufacturer initiative if pursuing pharmaceutical supply chains at the state and local level.